{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:10:29Z","timestamp":1788772229076,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.genhosppsych.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:01:38Z","timestamp":1785884498000},"page":"167-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["GLP-1 prescribing for individuals with schizophrenia-spectrum disorders in a safety net hospital"],"prefix":"10.1016","volume":"102","author":[{"given":"Sarosh","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva G.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany M.","family":"Gouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.genhosppsych.2026.08.002_bb0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.genhosppsych.2026.08.002_bb0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41569-020-00463-7","article-title":"Cardiovascular disease in patients with severe mental illness","volume":"18","author":"Nielsen","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.genhosppsych.2026.08.002_bb0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"issue":"8","key":"10.1016\/j.genhosppsych.2026.08.002_bb0020","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2337\/dc23-0294","article-title":"Relationship among diabetes, obesity, and cardiovascular disease phenotypes: a UK biobank cohort study","volume":"46","author":"Brown","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.genhosppsych.2026.08.002_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1395771","article-title":"Schizophrenia and type 2 diabetes risk: a systematic review and meta-analysis","volume":"15","author":"Dong","year":"2024","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.genhosppsych.2026.08.002_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021444","article-title":"Cardiovascular risk for patients with and without schizophrenia, schizoaffective disorder, or bipolar disorder","volume":"11","author":"Rossom","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.genhosppsych.2026.08.002_bb0035","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jacc.2022.06.017","article-title":"Severe mental illness and cardiovascular disease: JACC state-of-the-art review","volume":"80","author":"Goldfarb","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.genhosppsych.2026.08.002_bb0040","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.genhosppsych.2026.08.002_bb0045","series-title":"Clinical and economic evaluation of once-weekly Semaglutide for the treatment of type 2 diabetes in China","author":"Ruan","year":"2023"},{"issue":"2","key":"10.1016\/j.genhosppsych.2026.08.002_bb0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10557-024-07547-3","article-title":"Association between the magnitude of glycemic control and body weight loss with GLP-1 receptor agonists and risk of atherosclerotic cardiovascular disease: a systematic review and meta-analyses of randomized diabetes cardiovascular outcomes trials","volume":"39","author":"Gomes","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.genhosppsych.2026.08.002_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/eurjpc\/zwaf358","article-title":"Effect of semaglutide on mortality and cardiovascular events in patients at high cardiovascular risk: an updated systematic review and meta-analysis","volume":"33","author":"Spagnolo","year":"2026","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"10.1016\/j.genhosppsych.2026.08.002_bb0060","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamapsychiatry.2024.2412","article-title":"Semaglutide in psychiatry\u2014opportunities and challenges","volume":"81","author":"Agarwal","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.08.002_bb0065","article-title":"Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis","volume":"14","author":"Khaity","year":"2023","journal-title":"Front Psych"},{"issue":"11","key":"10.1016\/j.genhosppsych.2026.08.002_bb0070","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.genhosppsych.2026.08.002_bb0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","article-title":"Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-Centre, participant and investigator-blinded, randomised controlled trial in Australia","volume":"12","author":"Siskind","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.08.002_bb0085","series-title":"Drug Trial Snapshot: Ozempic","author":"Food, U. And D. Administration","year":"2018"},{"issue":"1","key":"10.1016\/j.genhosppsych.2026.08.002_bb0090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.genhosppsych.2026.08.002_bb0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J Am Pharm Assoc"},{"issue":"9","key":"10.1016\/j.genhosppsych.2026.08.002_bb0100","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7326\/M24-0019","article-title":"Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis","volume":"177","author":"Yeo","year":"2024","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.genhosppsych.2026.08.002_bb0105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/ANNALS-24-02870","article-title":"Trends in utilization of glucose-and weight-lowering medications after tirzepatide approval in the United States: a population-based cohort study","volume":"178","author":"Ostrominski","year":"2025","journal-title":"Ann Intern Med"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834326001672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834326001672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:40:39Z","timestamp":1788770439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834326001672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"alternative-id":["S0163834326001672"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2026.08.002","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 prescribing for individuals with schizophrenia-spectrum disorders in a safety net hospital","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}